Abstract
Assisted ventilation and hospitalization are significant drivers of aggregate annual costs and overall health burden in amyotrophic lateral sclerosis (ALS). An oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol (PB&TURSO) slowed functional decline in people living with ALS in the 6-month randomized, placebo-controlled phase of the CENTAUR trial. Here, we report final analyses of ALS progression events in CENTAUR inclusive of the long-term, follow-up open-label extension phase.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
